WO2008029138A3 - Peptides and methods - Google Patents

Peptides and methods Download PDF

Info

Publication number
WO2008029138A3
WO2008029138A3 PCT/GB2007/003355 GB2007003355W WO2008029138A3 WO 2008029138 A3 WO2008029138 A3 WO 2008029138A3 GB 2007003355 W GB2007003355 W GB 2007003355W WO 2008029138 A3 WO2008029138 A3 WO 2008029138A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polypeptide
cancer
relates
peptides
Prior art date
Application number
PCT/GB2007/003355
Other languages
French (fr)
Other versions
WO2008029138A2 (en
Inventor
Shahriar Behboudi
Original Assignee
Ucl Business Plc
Shahriar Behboudi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc, Shahriar Behboudi filed Critical Ucl Business Plc
Publication of WO2008029138A2 publication Critical patent/WO2008029138A2/en
Publication of WO2008029138A3 publication Critical patent/WO2008029138A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001181—Alpha-feto protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a recombinant or isolated polypeptide, wherein said polypeptide is or comprises a CD4+ T cell epitope; wherein said polypeptide is no more than 14 amino acids in length; and wherein said polypeptide comprises amino acid sequence selected from the group consisting of KVNFTEIQKL (AFP249-258 = SB94 = SEQ ID NO:4); LQTMKQEFLI (AFP545-554 = SB85 = SEQ ID NO:3); EMTPVNPGV (AFP489-497 = SB44 = SEQ ID NO:5); CLENQLPAFL (AFP86-95 = SB93 = SEQ ID NO:6); SSGEKNIFL (AFP343-351 = SB48 = SEQ ID NO: 8); and variants thereof. The invention also relates to other polypeptides as defined in the claims, and to their uses in the manufacture of medicaments for and treatment of cancer, preferably wherein said cancer expresses alpha fetoprotein, most preferably wherein said cancer is hepatocellular carcinoma (HCC).
PCT/GB2007/003355 2006-09-06 2007-09-06 Peptides and methods WO2008029138A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB617564.0 2006-09-06
GBGB0617564.0A GB0617564D0 (en) 2006-09-06 2006-09-06 Peptides and methods

Publications (2)

Publication Number Publication Date
WO2008029138A2 WO2008029138A2 (en) 2008-03-13
WO2008029138A3 true WO2008029138A3 (en) 2008-09-25

Family

ID=37232473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/003355 WO2008029138A2 (en) 2006-09-06 2007-09-06 Peptides and methods

Country Status (2)

Country Link
GB (1) GB0617564D0 (en)
WO (1) WO2008029138A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104371017B (en) * 2014-07-04 2018-03-16 嘉兴博泰生物科技发展有限公司 A kind of high efficient expression and the method for preparing outer secreting type people source AFP
KR101966139B1 (en) * 2017-04-20 2019-04-08 한국기초과학지원연구원 DIAGNOSTIC METHOD OF LIVER CANCER USING α-FETOPROTEIN DERIVED GLYCOPEPTIDES BY MASS SPECTROMETRY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022787A1 (en) * 1995-01-24 1996-08-01 Murgita Robert A Recombinant human alpha-fetoprotein and uses thereof
WO1998035981A1 (en) * 1997-02-13 1998-08-20 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer
WO2006031611A1 (en) * 2004-09-09 2006-03-23 Serometrix Llc Compositions and methods of using alpha-fetoprotein growth inhibitory peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022787A1 (en) * 1995-01-24 1996-08-01 Murgita Robert A Recombinant human alpha-fetoprotein and uses thereof
WO1998035981A1 (en) * 1997-02-13 1998-08-20 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer
WO2006031611A1 (en) * 2004-09-09 2006-03-23 Serometrix Llc Compositions and methods of using alpha-fetoprotein growth inhibitory peptides

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALI ET AL: "Activation of dendritic cells by local ablation of hepatocellular carcinoma", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 43, no. 5, November 2005 (2005-11-01), pages 817 - 822, XP005130182, ISSN: 0168-8278 *
ALISA AKEEL ET AL: "Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 SEP 2005, vol. 11, no. 18, 15 September 2005 (2005-09-15), pages 6686 - 6694, XP002476998, ISSN: 1078-0432 *
AYARU ET AL: "Alpha-fetoprotein specific CD4+ T cell responses are unmasked during transarterial embolisation in hepatocellular carcinoma", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 44, April 2006 (2006-04-01), pages S11, XP005537635, ISSN: 0168-8278 *
AYARU LAKSHMANA ET AL: "Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization", JOURNAL OF IMMUNOLOGY, vol. 178, no. 3, February 2007 (2007-02-01), pages 1914 - 1922, XP002476999, ISSN: 0022-1767 *
BUTTERFIELD LISA H ET AL: "A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 MAY 2006, vol. 12, no. 9, 1 May 2006 (2006-05-01), pages 2817 - 2825, XP002477000, ISSN: 1078-0432 *
HIROYA KOBAYASHI ET AL: "Defining MHC class II T helper epitopes for WT1 tumor antigen", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER-VERLAG, BE, vol. 55, no. 7, 1 July 2006 (2006-07-01), pages 850 - 860, XP019333258, ISSN: 1432-0851 *
RÖHN T A ET AL: "A Novel Strategy for the Discovery of MHC Class II -Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 65, no. 21, 1 November 2005 (2005-11-01), pages 10068 - 10078, XP002442801, ISSN: 0008-5472 *
ZHANG HONG-MEI ET AL: "Induction of alpha-fetoprotein-specific CD4-and CD8-mediated T-cell response using RNA-transfected dendritic cells", CELLULAR IMMUNOLOGY, vol. 239, no. 2, February 2006 (2006-02-01), pages 144 - 150, XP002476997, ISSN: 0008-8749 *

Also Published As

Publication number Publication date
WO2008029138A2 (en) 2008-03-13
GB0617564D0 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
AU2014253900B2 (en) Engineered phenylalanine ammonia lyase polypeptides
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
MX2008009493A (en) Novel peptide and use thereof.
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
IN2014CN02050A (en)
NZ604818A (en) Variants of activin iib receptor polypeptides and uses thereof
MX2009004147A (en) Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides.
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
MX2012005864A (en) Anti-orai1 antigen binding proteins and uses thereof.
MX2011008759A (en) Means and methods for manufacturing highly pure neurotoxin.
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
NZ600363A (en) Modified porcine somatotropin polypeptides and their uses
WO2006131749A3 (en) Scaffold
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2007142582A8 (en) Fluorescent proteins and genes encoding them
WO2008113970A3 (en) Peptides
WO2008005527A3 (en) Glucagon-like peptides and uses thereof
WO2008113536A8 (en) Neurotrophic peptides
WO2006097432A3 (en) Keratin-binding desmoplakin polypeptide sequences
WO2008029138A3 (en) Peptides and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804156

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07804156

Country of ref document: EP

Kind code of ref document: A2